F. Hoffmann-La Roche Ltd.

In News

Transforming autoimmune treatment: How data-driven therapies are changing patient outcomes - Roche

Roche - Jul 06, 2026

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) - Yahoo Finance UK

Yahoo Finance UK - Oct 16, 2026

Rona licenses ALK7-targeted RNAi therapy to Roche - BioWorld News

BioWorld News - Oct 13, 2026

Roche and Earendil forge $1.5bn bispecific discovery deal - Pharmaceutical Technology

Pharmaceutical Technology - Sep 25, 2026

Roche targets Novartis on IgAN market after Phase III win - Clinical Trials Arena

Clinical Trials Arena - Sep 24, 2026

Roche’s Annual Report 2025 - Roche

Roche - Jan 29, 2026

Change in Roche’s Board of Directors - Yahoo Finance

Yahoo Finance - Sep 23, 2026

Roche Bau 1 wh-p Ingenieure - World-Architects

World-Architects - May 15, 2026

Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical Technology

Pharmaceutical Technology - Jun 08, 2026

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss - Yahoo Finance UK

Yahoo Finance UK - Oct 10, 2026

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer - Yahoo Finance UK

Yahoo Finance UK - Oct 09, 2026

Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases - Yahoo Finance UK

Yahoo Finance UK - Sep 17, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment